Clistin® Maleate: Clinical Appraisal of a New Antihistaminic. Henry D. Beale, Frank F.A. Rawling and Karl D. Figley. Journal of Allergy 25:521-524, November, 1954. The initial Study was conducted by three prominent allergy specialists in Toledo, OH. The Study included two strengths of carbinoxamine maleate: 4mg and 6mg. 126 patients (90% suffered from allergic rhinitis) were treated with each of the three options: 4mg, 6mg and placebo. Researchers made several key observations: action began in about 30 minutes 4mg dose was more effective (87% of patients noted relief) than the 6mg tablet (80% of patients noted relief). 1% (1 patient) reported severe sedation /drowsiness 3% (4 patients) reported moderate sedation / drowsiness 11% (14 patients) reported mild sedation / drowsiness 85% of the patients reported no sedation or drowsiness in those patients reporting drowsiness, the condition disappeared after a few days continued use. There was no significant report (less than 1%) of any other side effects: nausea, dizziness, insomnia, or headache. History / ANDA / Clinical Studies / Monographs / Resources / Home McNeil Laboratories, Inc.® and Clistin® are registered trademarks of McNeil Laboratories, Inc., Fort Washington, PA 19034. PALGIC® is a registered trademark of Pamlab LLC, Covington, LA, 70433